Johnson & Johnson Stock News

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, w...

Am Dienstag werden Anleger ganz besonders auf die Zahlen bei Johnson & Johnson, Bank of America, Citigroup, J.B. Hunt sowie United Airlines schauen.

U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.

Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists

CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week. He pinpointed earnings reports from major banks like Goldman Sachs, as well as Johnson & Johnson and Netflix,

Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operationa...

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.

The Company spend billions to produce 100% of its key medicines for Americans in the U.S.